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Cytotoxic T-lymphocyte-associated protein 4-Ig
effectively controls immune activation and
inflammatory disease in a novel murine model of
leaky severe combined immunodeficiencyStephanie Humblet-Baron, MD, PhD,a,b Susann Sch€onefeldt, MSc,a,b Josselyn E. Garcia-Perez, MSc,a,b
Frederic Baron, MD, PhD,c Emanuela Pasciuto, PhD,a,b and Adrian Liston, PhDa,b Leuven and Liege, BelgiumBackground: Severe combined immunodeficiency can be caused
by loss-of-function mutations in genes involved in the DNA
recombination machinery, such as recombination-activating
gene 1 (RAG1), RAG2, or DNA cross-link repair 1C (DCLRE1C).
Defective DNA recombination causes a developmental block in
T and B cells, resulting in high susceptibility to infections.
Hypomorphic mutations in the same genes can also give rise to a
partial loss of T cells in a spectrum including leaky severe
combined immunodeficiency (LS) and Omenn syndrome (OS).
These patients not only experience life-threatening infections
because of immunodeficiency but also experience inflammatory/
autoimmune conditions caused by the presence of autoreactive
T cells.
Objective: We sought to develop a preclinical model that fully
recapitulates the symptoms of patients with LS/OS, including a
model for testing therapeutic intervention.
Methods: We generated a novel mutant mouse (Dclre1cleaky)
that develops a LS phenotype. Mice were monitored for
diseases, and immune phenotype and immune function were
evaluated by using flow cytometry, ELISA, and histology.
Results: Dclre1cleaky mice present with a complete blockade of
B-cell differentiation, with a leaky block in T-cell differentiation
resulting in an oligoclonal T-cell receptor repertoire and
enhanced cytokine secretion. Dclre1cleaky mice also had
inflammatory symptoms, including wasting, dermatitis, colitis,
hypereosinophilia, and high IgE levels. Development of a
preclinical murine model for LS allowed testing of potential
treatment, with administration of cytotoxic T-lymphocyte-
associated protein 4-Ig reducing disease symptoms and
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Severe combined immunodeficiency (SCID) disorders are
characterized by a profound defect in the adaptive immune
system with a partial or total loss of function of T and B cells.
Patients are highly susceptible to severe opportunistic infections,
and their survival expectancy is limited unless they receive early
allogeneic hematopoietic stem cell transplantation. An important
cause of SCID is mutation in genes, such as recombination-
activating gene 1 (RAG1), RAG2, DNA cross-link repair 1C
(DCLRE1C), and DNA ligase 4 (LIG4), which produce proteins
that are part of the DNA recombination machinery. During the
V(D)J recombination of the T-cell receptor (TCR) or B-cell re-
ceptor (BCR), RAG1 and RAG2 recognize the recombination
signal sequence and cleave double-stranded DNA, followed by
formation of the hairpin loop at the end of the open DNA. In com-
plex with other proteins, ARTEMIS (the product of DCLRE1C)
then cleaves these hairpin loops to allow ligation of the newly
formed DNA strand by DNA ligase IV (the product of LIG4).
In the absence of any of these components, defective V(D)J
recombination blocks the formation of a functional TCR or
BCR, leading to an early block of T- and B-cell differentiation.1
In addition to the typical SCID phenotype, hypomorphic
mutations in the RAG1, RAG2, and DCLRE1C genes can cause
Omenn syndrome (OS) and leaky severe combined immunodefi-
ciency (LS). OS is characterized by early and severe inflamma-
tory symptoms, including generalized erythroderma, diarrhea,
hepatosplenomegaly, lymphadenopathy with hypereosinophilia,
and increased IgE levels. Unlike SCID, T cells are detected in
the blood of patients in the absence of maternal engraftment
and demonstrate peripheral activation and oligoclonal expansion
of self-reactive T cells.2 Patients with LS show even higher levels
of blood T cells (although still reduced relative to those in healthy
subjects) of an oligoclonal nature.2 Patients with LS can present
with a later clinical onset of disease with combined immunodefi-
ciency and immune dysregulation, leading to autoimmune mani-
festations, mostly autoimmune cytopenia. Both patients with OS
and those with LS are highly susceptible to cancer of lymphoid
origin.3 In most patients with OS and LS, residual activity of
the protein is detected. Specifically, large deletions and mutations
in the catalytically functional domains (b-lactamase and b-CASP1
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and SCID, whereas mutations in the C-terminal domain can result
in OS/LS phenotypes.4 OS and LS appear to lie on a spectrum of
immunodeficiency, with potential for similar mutations to mani-
fest with different clinical presentations.3,5
A diverse set of hypotheses have been formulated to explain the
coexistence of autoimmunity and immunodeficiency in patients
with OS/LS.6 However, the lack of preclinical models for LS/OS
with ARTEMIS deficiency has restricted both a functional under-
standing of the immune processes occurring and also the testing
of therapeutic tools. Here we developed a novel LS mouse model
caused by a hypomorphic point mutation in Dclre1c. Mutant
mice have a macroscopic phenotype similar to that of patients
with LS, including the presence of peripheral T-cell lymphocytes,
development of spontaneous inflammatory diseases, and a high
incidence of lymphoma development. Importantly, administration
of the immunosuppressive drugcytotoxicT-lymphocyte-associated
protein 4-Ig (CTLA4-Ig) resulted in control of inflammation and
improved disease-free survival in comparison with control mice,
identifying CTLA4-Ig as a potential treatment for patients with LS.
METHODS
Mice
Founder C57BL/6 male mice were treated with 100 mg/kg N-ethyl-N-nitro-
sourea (ENU) and bred to Foxp3GFP female mice to generate the Dclre1cleaky
strain.7 First-generation male offspring were backcrossed to Foxp3GFP female
mice to produce second-generation offspring, which were in turn intercrossed
to produce the third generation for phenotype screening. Phenotype screening
involved flow cytometric analysis for CD4 and Foxp3 (GFP) and identification
of mice with values for the percentage of GFP1 cells (within the CD41 popu-
lation) more than 2 SDs from the norm. Identified variant offspring were inter-
crossed to produce the C57BL/6.Foxp3GFP.Dclre1cleaky mutant mouse strain.
The leaky mutation was identified by means of all-exome sequencing and
confirmed by using Sanger sequencing.
CTLA4-Ig (abatacept [Orencia]; Bristol-Myers Squibb, New York, NY)
was administrated to C57BL/6.Foxp3GFP.Dclre1cleaky and littermate control
mice starting at 8 weeks of age at a dose of 25 mg/kg administered intraperi-
toneally every other week. Micewere maintained in specific pathogen-free fa-
cilities of the University of Leuven. All experiments were approved by the
University of Leuven ethics committee.
Western blotting
Thymocytes were homogenized in lysis buffer consisting of 100 mmol/L
NaCl, 50 mmol/L Tris-HCl (pH 7.5), 1% Triton X-100, 2 mmol/Ldithiothreitol, 1 mmol/L EDTA, phosphatase inhibitor (Sigma-Aldrich, St
Louis, Mo), and protease inhibitor (Pierce, Rockford, Ill) and then incubated
on ice for 30 minutes. Cells were sonicated, and lysate was prepared. The
NuPAGE Precast Gel System was used for Western blotting (Life technolo-
gies, Grand Island, NY). Ten to 20 mg of lysate was separated on 4-12% bis-
Tris acrylamide gels and blotted on a polyvinylidene difluoride membrane
(GEHealthcare, Fairfield, Conn). Membranes were incubated with polyclonal
IgG rabbit anti-mouse/human Artemis (1:1000, PA5-26741; Thermo Scien-
tific, Waltham, Mass) and mouse anti–glyceraldehyde-3-phosphate dehydro-
genase (GAPDH; 1:10000, GA1R; Thermo Scientific) and developed by using
Western Lightning Plus-ECL (PerkinElmer, Waltham, Mass) and the imaging
system G:Box XRQ (Syngene, Cambridge, United Kingdom). Quantification
was performed with AIDA software (version 5.0; Raytest, Straubenhardt,
Germany).TCR Vb CDR3 size spectratype analysis
Total splenocytes were harvested and conserved in RNA Later stabili-
zation reagent (Trizol, Thermo Fisher Scientific). RNA was then extracted
with the RNEasy Mini Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s instructions. Genomic DNA was removed by using recom-
binant RNase-free DNaseI (Roche, Mannheim, Germany). cDNA was
synthesized from RNA (2 mg) by using oligo(dT)18 primers with the Tran-
scriptor First Strand cDNA Synthesis Kit (Roche). Seminested PCR was
performed with sense primers for a panel of murine Vb families and
2 Cb anti-sense primers (Integrated DNA Technologies, Leuven, Belgium),
as previously described. CDR3 size spectratype analysis was performed with
GeneMapper version 4.0 Software (Applied Biosystems, Foster City, Calif).Flow cytometry
Single-cell suspensions were prepared from mouse thymus, bone marrow,
spleen, and pooled lymph nodes (cervical, inguinal, mesenteric, axillary, and
brachial). For intracellular cytokine staining, lymphocytes were plated at
53 105 cells/well in 96-well tissue-culture plates in complete RPMI contain-
ing phorbol 12-myristate 13-acetate (50 ng/mL; Sigma-Aldrich), ionomycin
(250 ng/mL; Sigma-Aldrich), and monensin (1/1500; BD Biosciences, San
Jose, Calif) for 4 hours at 378C. All cells were fixed with BD Cytofix (BDBio-
sciences) or fixed and permeabilized with the eBioscience Foxp3 staining kit
(eBioscience/Affymetrix, San Diego, Calif). Anti-murine antibodies included
anti-CD4 (RM4-5), anti-CD8a (53-6.7), anti-Foxp3 (FJK-16s), anti-CD25
(PC61.5), anti-CTLA4 (UC10-4B9), anti-CD69 (H1.2F3), anti-CD44 (IM7),
anti–CD62 ligand (MEL-14), anti-B220 (RA3-6B2), anti-CD19 (eBio1D3),
anti-CD43 (eBioR2/60), anti-IgM (II/41), anti-IgD (11-26c), anti-NK1.1
(PK136), anti-Gr1 (RB6-8C5), anti-CD11b (M1/70), anti-CD127 (A7R34),
anti-KLRG1 (2F1), anti-PD1 (J43), anti-CD3 (145-2c11), anti-CD24 (M1/
69), anti-Qa2 (1-1-2), anti-NKG2D (CX5), anti-Ly49D (4E5), anti-CD122
(TM-b1), anti–IFN-g (XMG1.2), anti–IL-4 (BVD6-24G2), and anti–IL-17
(eBio17B7) from eBioscience and anti-Ki67 (B56) and anti–Siglec-F (E50-
2440) from BD Biosciences.Histology
Mouse tissues were preserved in 10% formalin and processed into paraffin-
embedded tissue blocks by Histology Consultation Services (Everson, Wash).
Each block had thin (approximately 4-mm) sections cut on a microtome,
mounted on glass slides, and stained with hematoxylin and eosin. Pathological
diagnosis was performed by Biogenetics Research Laboratories, Greenbank,
Wash.ELISA-MSD
IgE titers in individual serum samples were determined by using a mouse
IgE ELISA Ready-SET-Go! Kit (eBioscience), according to the manufac-
turer’s protocol. Cytokine serum levels were quantified by usingV-Plexmouse
Pro-inflammatory panel MSD (Meso Scale Discovery, Rockville, Md) plates,
according to the manufacturer’s instructions.
FIG 1. New point mutation identified in Dclre1cleaky mice. By using ENU mutagenesis, leaky mice with a
point mutation in ARTEMIS were identified. A, Leaky mice were identified with a low level of peripheral
Treg cells in the blood. B, Sanger sequencing of Dclre1c, encoding for ARTEMIS, in wild-type and leaky
mice confirmed a T-to-C mutation resulting in a lysine-to-proline mutation in amino acid change. C,Muta-
tion confers a L219P substitution (star) between the 2 active domains of the protein (b-lactamase, SM00849,
and the b-CASP domain PF07522). D, L219P mutation is located in a region conserved across species. E,
Western blot (left) and relative expression (right) of ARTEMIS protein in thymocytes from wild-type
(n 5 5) and Dclre1cleaky (n 5 5) mice. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.
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Single comparisons were analyzed by using the nonparametric Mann-
Whitney U test. All statistical analyses were carried out with GraphPad Prism
(GraphPad Software, La Jolla, Calif). Data from mice diagnosed with tumors
were excluded from cell subset and cytokine analysis. Homology alignment
was performed by using HomoloGene and BLAST.RESULTS
An ENU-induced mutation in ARTEMIS results in an
LS phenotype
In a screen for modulators of regulatory T (Treg) cell numbers,
we exposed C57Bl/6 mice to the ENU mutagen and intercrossed
with the Foxp3GFP strain before flow cytometry–based screening
for Treg cell numbers. One pedigree was isolated with the presen-
tation of low CD41 T-cell counts and disproportionately low Treg
cell counts within the blood (Fig 1, A). All-exon sequencing iden-
tified a point mutation in Dclre1c, the gene encoding ARTEMIS.
This transition mutation (c.656T>C), named leaky, generated an
amino acid substitution in position 219 coding for a proline
instead of a leucine (Fig 1, B). The mutated residue is located be-
tween the b-lactamase and b-CASP domains in a highly
conserved region (Fig 1, C andD). Western blot analysis detected
a strong presence of ARTEMIS expression in the leaky mouse
thymus, indicating that the mutation did not affect protein expres-
sion (Fig 1, E).
The discrepancy between Dclre1cKO mice,8 with near-
complete T cell deficiency, and Dclre1cleaky mice, with reduced
but detectable numbers of T cells in all mice, spurred further char-
acterization of T-cell development in themutant strain.Dclre1cKOmice display a block in thymocyte development at the double-
negative stage during VDJ rearrangement.8 Dclre1cleaky mice
also exhibited decreased absolute numbers of total thymic cells
in comparison with wild-type mice (Fig 2, A). Furthermore, per-
centages of double-negative cells were enhanced in ARTEMIS
mutant mice compared with those in wild-type mice in both
young and old animals (Fig 2, B). Double-positive cell counts
were severely reduced in leaky mice (Fig 2, C); however, unlike
knockout animals, both single-positive (SP) CD81 T cells (SP
CD81) and CD41 T cells (SP CD41) were detected in Dclre1-
cleaky mice (Fig 2, D and E). This result indicates a hypomorphic
allele, allowing a fraction of thymocytes to rearrange competent
TCRs for further progress to the next developmental stage.
Detailed immunophenotyping of the thymus showed a dominant
presence of recirculating cells within the SP T-cell population in
Dclre1cleaky mice in comparison with wild-type animals (see Fig
E1 in this article’s Online Repository at www.jacionline.org).
Interestingly and in line with the initial phenotype screening,
Foxp31 Treg cell counts were significantly decreased in both
young and old mutant animals (Fig 2, F). In absolute numbers
all measured T-cell subsets in the thymus were decreased in leaky
mice, but substantial numbers of T cells were still able to rear-
range their TCR and mature to the periphery (see Fig E1).
The LS phenotype in human subjects has been described as a
strongly reduced but still present number of CD31 T cells in
the peripheral blood caused by hypomorphic mutation in
known SCID genes, including DCLRE1C.2 In Dclre1cleaky mice
both mature CD41 and CD81 T cells were present in the spleen,
although at significantly lower numbers (Fig 3, A-C, and see Fig
E2, D, in this article’s Online Repository at www.jacionline.org).
FIG 2. Partial T-cell developmental block in Dclre1cleaky mice. The thymi of wild-type (WT) and Dclre1cleaky
mice were evaluated at 8 weeks and 8 to 10months of age. Thymic cell subsets were analyzed by using flow
cytometry. A, Thymus absolute cell numbers. B, Percentage of double-negative cells from total cells. C, Per-
centage of double-positive cells from total cells. D, Percentage of CD81 single-positive cells from total cells.
E, Percentage of CD41 single-positive cells from total cells. F, Percentage of Treg cells from single-positive
CD41 cells. Median and individual data points are shown. Pooled data from up to 11 experiments are
shown: wild-type 8-week-old mice (n 5 3), Dclre1cleaky 8-week-old mice (n 5 8), wild-type 8- to 10-month-
old mice (n 5 14), and Dclre1cleaky 8- to 10-month-old mice (n 5 27).
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tantly, in almost all leaky mice analyzed, Treg cell numbers were
disproportionately reduced (Fig 3, D, and see Fig E2, E). Patients
with an LS phenotype have a restricted T-cell repertoire.2 This
prompted us to analyze the diversity of the TCR repertoire in
the spleens of wild-type and leakymice through TCR spectratyp-
ing. Consistent with the patient phenotype, we observed that
Dclre1cleaky mice displayed a very limited TCR repertoire
compared with wild-type mice (Fig 3, E). Together, these results
indicate that leaky mice recapitulate the oligoclonal nature of the
T-cell repertoire observed in patients with LS because of
restricted T-cell differentiation.
Regarding other immune cell compartments, B cells were
almost absent in leakymice, with an early block between the pro–
B-cell and pre–B-cell stage during bone marrow development
with a conserved pro–B-cell compartment (median, 3.3%
from total bone marrow cells for wild-type mice vs 3.4% for
Dclre1cleaky mice) and a near-absent pre–B-cell compartment
(median, 4.3% from total bone marrow cells for wild-type mice
vs 0.2% for Dclre1cleaky mice; P 5 .003; Fig 3, F and G). The
percentage of natural killer and myeloid cells was increased in
ARTEMIS mutant mice because of the reduction in T- and
B-lymphocyte numbers, but absolute numbers were similar
(Fig 3, H-J). However, an altered activation profile was
observed in natural killer cells from Dclre1cleaky mice (seeFig E2,F andG). ThereforeDclre1cleakymice fit the immunologic
criteria for LS, with severe but partial defects in TCR/BCR
rearrangement but otherwise intact immune systems.Leaky mice develop inflammatory pathology
Published mice with mutations in ARTEMIS phenocopy the
classical SCID presentation of patients with DCLRE1C muta-
tions,8-11 with defects in Tand B cells causing immunodeficiency
but no spontaneous disease,8-11 apart from an increased incidence
of tumor under a specific backcross.12 By contrast, Dclre1cleaky
mice recapitulate the LS phenotype present in a subset of
DCLRE1C patients13 with spontaneous immune activation. The
clonal T cells from leakymice that underwent successful TCR re-
arrangement demonstrated high levels of oligoclonal peripheral
expansion (Fig 3, E), with enhanced proliferation (Fig 4, A, and
see Fig E3, A, in this article’s Online Repository at www.
jacionline.org). These expanded cells were mainly of an effector
phenotype, with a significantly decreased naive T-cell compart-
ment (Fig 4, B and C, and Fig E3, B and C). Interestingly,
CD122 expression was increased in CD81 central memory T
(TCM) cells, suggesting that Dclre1cleaky T cells might have a
higher reliance on IL-15 for homeostasis (see Fig E3, D). This
is further illustrated by an expansion over time of this specific
CD81 TCM cell population in Dclre1cleaky mice, whereas this
FIG 3. Dclre1cleaky mice have an LS phenotype in the periphery. Spleens from wild-type (WT) and
Dclre1cleaky mice were evaluated at 8 weeks and between 8 and 10 months of age. Splenic cell subsets
were analyzed by using flow cytometry. A, Absolute numbers of CD81 and CD41 T cells in the spleen at
8 to 10months. B-D, Percentage of CD41 T cells (Fig 3, B), CD81 T cells (Fig 3,C), and Treg cells (CD41Foxp31
cells; Fig 3, D). E, Spectratyping CDR3 analysis of TCR Vb diversity. Representative mice and Vb families are
presented. Black bars indicate saturation of signal intensity. F, Representative bone marrow B-cell
maturation flow cytometric plots (left) and percentage of early B-cell progenitors (pro–B cells and pre–B
cells graph; right). G and H, Percentage of splenic B cells (Fig 3, G) and natural killer cells (Fig 3, H). I and
J, Absolute numbers of splenic natural killer cells (Fig 3, I) and neutrophils (Gr-1high/CD11bhigh cells;
Fig 3, J). Median and individual data points are shown. Fig 3, A-D and F-J, show pooled data from up to
11 experiments with wild-type 8-week-old mice (n 5 3), Dclre1cleaky 8-week-old mice (n 5 from 7 to 8),
wild-type 8- to 10-month-old mice (n 5 from 3 to 14), and Dclre1cleaky 8- to 10-month-old mice (n 5 from
8 to 27).
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see Fig E3, B and C). Indeed, splenic absolute numbers of CD81
TCM cells increase 10-fold in old (median, 0.47 3 106) versus
young (median, 0.043 106; P <.001)Dclre1cleakymice, although
the overall number remains less than the wild-type cell number
(median, 3.1 3 106 and 2.7 3 106 cells [not significant] in old
and young mice, respectively).
The high T-cell activation inDclre1cleakymicewas also demon-
strated by the increased percentage of cells expressing CD69 at
their cell surfaces, a marker of early T-cell activation (Fig 4, D,
and see Fig E3, E). By contrast, no difference in expression of
CD127, KLRG1, or PD1 was observed in CD81 T-cell subsets
(Fig 4, E); however, a transient boost in short-lived effector cells
(SLECs) was observed in leaky mice at young ages, with resolu-
tion in older mice (see Fig E4 in this article’s Online Repository at
www.jacionline.org).To determine whether the activated T cells in leaky mice were
producing an inflammatory environment, we assessed cytokine
release. Within Dclre1cleaky mice, numbers of TH1 (IFN-
g–secreting CD41 T cells), TH2 (IL-4–secreting CD4
1 T cells),
and TH17 (IL-17–secreting CD4
1T cells) cells were all increased
compared with those in wild-type animals (Fig 4, F, and see Fig
E3, F), with serum increases in IFN-g levels also observed (Fig
4, G).
The inflammatory T-cell phenotype of Dclre1cleaky mice was
associated with immune pathology. More than 50% of leaky
mice had a wasting disease with lower weight, poor grooming,
an abnormal hunched posture, or signs of severe dermatitis (Fig
5, A andB, and see Fig E5, A-C, in this article’s Online Repository
at www.jacionline.org). When evaluated based on histology, all
leaky analyzed mice showed signs of lymphoreticular infiltrates
in different organs, including the lung, liver, gastrointestinal tract,
FIG 4. Dclre1cleaky mice have increased T-cell activation and proinflammatory cytokine levels in serum.
Splenic T cells from wild-type (WT) and Dclre1cleaky mice were evaluated at 8 weeks and 8 to 10 months
of age. T-cell subsets were analyzed by using flow cytometry. A, Percentage of CD41 and CD81 T cells ex-
pressing Ki67. B and C, T cells were characterized as CD62L1CD442 naive cells, CD62L1CD441 TCM cells,
and CD62L2CD441 effector memory T cells (TEM) for CD41 (Fig 4, B) and CD81 subsets (Fig 4, C).D, Percent-
age of CD41 and CD81 T cells expressing CD69. E, Percentage of CD81 T cells expressing CD127, KLRG1, and
PD1. F, Splenocytes were stimulated in vitro for 4 hours with phorbol 12-myristate 13-acetate/ionomycin,
and CD41 T cells were evaluated for cytokine secretion, including IFN-g, IL-4, and IL-17. G, Serum levels
of IFN-g and IL-4. Median and individual data points are shown. Pooled data from up to 11 experiments
are shown: wild-type 8-week-old mice (n 5 3), Dclre1cleaky 8-week-old mice (n 5 8), wild-type 8- to 10-
month-old mice (n 5 from 4 to 14), and Dclre1cleaky 8- to 10-month-old mice (n 5 from 6 to 27).
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(Fig 5, C). Disease was accompanied by a high number of eosin-
ophils in both the spleen and peripheral blood (Fig 5, D), and a
substantial increase in IgE levels (>50,000 ng/mL) was detected
in the sera of 26% of leaky mice (compared with 7% of age-
matched control mice). Consistently, IL-5 in the sera of
Dclre1cleaky mice was detected at a higher level (see Fig E6 in
this article’s Online Repository at www.jacionline.org). In addi-
tion, tumors of a lymphoid origin developed in 15% of Dclre1-
cleaky mice at 8 to 10 months of age (Fig 5, A and E, and see
Fig E5, D), a level similar to that of spontaneous tumors reported
in patients withDCLRE1Cmutation and an LS phenotype.3,4 The
combined effect was an increased premature mortality rate in
ARTEMIS mutant mice (18% at 8 months of age compared
with 0% in wild-type siblings at the same age). This immune pa-
thology places the Dclre1cleaky mouse strain on the spectrum of
clinical immune pathology observed in patients with LS or OS
and DCLRE1C mutations.CTLA4-Ig treatment prevents immune pathology in
ARTEMIS mutant mice with LS
The development of a new animal model that recapitulated
the key clinical features of LS allowed the testing of potentialtherapeutic interventions. The Dclre1cleaky phenotype was asso-
ciated with peripheral T-cell activation, including high IL-4,
high IgE, and increased eosinophil levels, which are character-
istics of Treg cell deficiency and TH2-mediated disease. These
observations prompted us to treat leaky mice with CTLA4-Ig
to investigate whether disease could be prevented by this treat-
ment, which was shown previously to be effective in suppress-
ing TH2 responses in mice with low Treg cell numbers.
14
Dclre1cleaky and littermate control mice (including heterozygous
mice) were left untreated or received 25 mg/kg CTLA4-Ig every
second week from the age of 8 weeks. Untreated leaky mice
showed normal weight curves until 6 months of age, at which
point wasting (Fig 6, A) and premature mortality (27% of
mice) were noted (Fig 6, B). By contrast, the CTLA4-Ig–treated
leaky mice did not exhibit wasting, and no premature mortality
was observed (Fig 6, A and B). Furthermore, none of the
Dclre1cleaky mice receiving CTLA4-Ig treatment had any symp-
toms of skin inflammation (Fig 6, C, and see Fig E7 in this ar-
ticle’s Online Repository at www.jacionline.org) or hyper-IgE
(Fig 6, D). These observations indicate the efficacy of
CTLA4-Ig for the autoimmune-related manifestations of LS.
By contrast, however, colitis was not improved with CTLA4-
Ig treatment, and 15% of Dclre1cleaky mice treated with
CTLA4-Ig had tumors, an incidence similar to the untreated
FIG 5. Dclre1cleaky mice are affected by inflammatory diseases and lymphoma. Mice were evaluated at 8 to
10 months of age for disease incidence and markers of inflammation. A, Thirty-four leaky mice were eval-
uated for pathological symptoms, and each circle represents an individual mouse. B,Mouse weight. C, His-
tology of lung, liver, skin, and colon of both wild-type (WT) and Dclre1cleaky mice. Arrows show
lymphoreticular infiltrates. D, Percentage of eosinophils into the spleen and blood. E, Representative histol-
ogy of a lymphocytic lymphoma from the thymus, infiltrating the liver and lung. Fig 5, A, shows pooled data
from up to 11 experiments. Fig 5, B, shows pooled data from 5 experiments, wild-type mice (n 5 8), and
Dclre1cleaky mice (n 5 17). Fig 5, C and E, show a representative histologic image. Scale bars 5 50 mm.
Fig 5, D, represents 1 experiment: wild-type mice (n 5 from 3 to 9) and Dclre1cleaky mice (n 5 from 4 to 7).
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vent the development of thymic lymphoma (Fig 6, C).
Although the precise mechanism of action of CTLA4 is still
under debate, there is strong evidence suggesting that reducingligand access to the costimulation molecule CD28 constitutes one
of its principal functions.15 An immunologic analysis of the ef-
fects of CTLA4-Ig treatment on control and leaky mice found
that the main immune phenotype caused by CTLA4-Ig treatment
FIG 6. CTLA4-Ig treatment prevents immune pathology in Dclre1cleakymice. Dclre1cleakymice and littermate
controls (Ctrl) were followed up for a longitudinal study with and without CTLA4-Ig treatment (25 mg/kg
every 2 weeks starting at 8 weeks). Mice were evaluated at 40 weeks of age. A, Weight curve. B, Survival
curve. C, Adverse events/pathological observations were monitored in all mice at the time of death, and
each circle represents an individual mouse. D, IgE concentration in serum. Means and SEMs are shown
for Fig 6, A, and medians and individual data points are shown for Fig 6, D. At the start of the study (Fig
6, A and B), untreated control mice (n5 11) and untreated Dclre1cleakymice (n5 11), CTLA4-Ig–treated con-
trol mice (n5 12), and CTLA4-Ig–treatedDclre1cleakymice (n5 13) were used. At the time of analysis (Fig 6, C
and D), untreated control mice (n 5 10), untreated Dclre1cleaky mice (n 5 9), CTLA4-Ig–treated control mice
(n 5 12), and CTLA4-Ig–treated Dclre1cleaky mice (n 5 13) were used.
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including a further reduction of the Treg cell subset (Fig 7, A-C,
and see Fig E8, A and B, in this article’s Online Repository at
www.jacionline.org). This is in accordance with the fact that
CD28 costimulation is critical for T-cell peripheral survival,16
with a more profound requirement present in Treg cells.17,18
Furthermore, we observed a lower percentage of CD41 T-cell
proliferation (Fig 7, D, and see Fig E8, C) and activation (Fig 7,
E, and see Fig E8, D) in the spleen and lymph nodes after
CTLA4-Ig treatment. Regarding cytokine secretion, there was a
strong reduction in the absolute number of cytokine-secreting T
cells because of the generic blockade on T-cell activation (Fig
7, F-H), specifically in TH2 cells as a reflection of better control
of TH2 over TH1 by CTLA4-Ig.
14 In addition, levels of IFN-gand TNF-a were significantly lower in the serum of Dclre1cleaky
mice receiving CTLA4-Ig (Fig 7, I and J). Finally, it is worth
noting that all significant immune differences induced by
CTLA4-Ig treatment were observed in both littermate control
and Dclre1cleaky mice, indicating that the successful ablation of
immune pathology in leaky mice is driven by the same immuno-
logic processes initiated by CTLA4 in control mice.DISCUSSION
Although complete T-cell deficiency presents as profound
immunodeficiency, incomplete forms, prototypically OS and LS,
manifest as a paradoxical copresentation of immunodeficiency
and immune dysregulation with spontaneous inflammatory/
FIG 7. CTLA4-Ig treatment effectively decreases inflammation in Dclre1cleaky mice. Dclre1cleaky mice and
littermate controls (Ctrl) received CTLA4-Ig (25 mg/kg) every 2 weeks starting at 8 weeks of age. Mice
were evaluated at 40 weeks of age for the immune cell compartment in the spleen. A, Kinetics of CD41 T
cells in blood at 3, 6, and 9 months of age. B, Percentage of total CD41 T cells. C, Percentage of Treg
(CD41Foxp31 cells) within CD41 T cells. D and E, Ki671 cells (Fig 7, D) and CD691 cells (Fig 7, E). F-H, Abso-
lute number of TH1 (IFN-g–secreting CD4
1 T cells Fig 7, F), TH2 (IL-4–secreting CD4
1 T cells; Fig 7, G), and
TH17 cells (IL-17–secreting CD4
1 T cells; Fig 7, H). I and J, Serum level of IFN-g (one very high value for
Dclre1cleaky is not shown; Fig 7, I) and TNF-a (Fig 7, J). Medians and individual data points are shown.
Fig 7, A, I, and J, represent 1 experiment, and Fig 7, B-H, represent data of 2 experiments. Untreated control
mice (n 5 from 3 to 9) and untreated Dclre1cleaky mice (n 5 from 3 to 9), CTLA4-Ig–treated control mice
(n 5 from 5 to 12) and CTLA4-Ig–treated Dclre1cleaky mice (n 5 from 5 to 11) were used.
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forward to explain this paradox at the immunologic level,
including a mismatch between available effector and Treg cell
clones after oligoclonal expansion, reduced efficiency of thymic
tolerance processes in the abnormal thymic tissue present, or a
hyperstimulatory phenotype of dendritic cells created by periph-
eral T-cell deficiency.6,19 However, a limited range of preclinical
models has hampered the ability to test these models and develop
therapeutic strategies.
Mutations in ARTEMIS drive clinical phenotypes that fall in
the SCID-OS-LS spectrum. Mouse models, by contrast, show a
much more restricted phenotypic range because of the concen-
tration on ‘‘knockout’’ mutations. Standard ARTEMIS knockout
mice possess a SCID-like phenotype, although the presence of T
cells in the periphery suggests a partial redundancy of ARTEMIS
for TCR rearrangement in mice.8 Mutations in the C-terminal
domain of ARTEMIS, which are more likely to promote a leaky
phenotype in patients,4 have only a partial block in B- and T-
cell development10; however, none of these models present with
clinical symptoms analogous to those experienced by patients
with LS. In the ARTEMIS mouse model reported here, point mu-
tation L219P results in a clinical phenotype that is very similar to
that of patients with LS/OS, with inflammatory disorders in mul-
tiple organs. Specifically, Dclre1cleaky mice recapitulate key fea-
tures of patients with LS/OS, including dermatitis, wasting
disease, splenomegaly, inflammatory cytokines, high IgE levels,
and hypereosinophilia. With symptomatic development in oldermice, leaky mice fit within the LS clinical range, although with
similarities to OS. Although no mutation in the 219 position has
been described in a patient with SCID, a mutation in the nearby
residue 228 within the same conserved region has been reported
in a patient with a SCID phenotype and partial VDJ recombina-
tion and DNA repair activity in vitro.4
The serendipitous development of an LS preclinical model
allowed for dissection of potential tolerance breakpoints and thus
testing of intervention strategies. The most striking observation
was the low number of Treg cells found in both the thymus and
periphery. One could speculate that the only allowed V(D)J
rearrangement in patients with LS is detrimental to Treg cell
formation, maintenance, or both because of selection of TCRwith
a specific affinity.20 This low Treg cell phenotype can account for
the inflammatory TH1/TH2 profile observed in Dclre1c
leaky mice
because of the asymmetry in Treg cell control over the 2 immune
arms.14 Additional homeostatic ‘‘space filling’’ pressures can be
extrapolated from the oligoclonal expansion and adoption of the
effector memory T-cell phenotype observed in T cells. The logical
extension of this immunologic presentation is that therapeutic
intervention requires substitution for Treg cell deficiency,
enhanced suppression of the TH2 response, and a counteraction
of the enhanced CD80/CD86 stimulatory profile of lymphopenic
dendritic cells.
Current treatment for inflammatory manifestation in patients
with LS/OS is based on nonspecific immunosuppressive drugs,
such as corticosteroids and cyclosporine.13,21 Although these
J ALLERGY CLIN IMMUNOL
nnn 2017
10 HUMBLET-BARON ET ALtreatments show some limited success, the combination of limited
efficacy and undesirable side effects leave room for clinical
improvement. New therapeutic approaches are being directed to-
ward better targeted and specific treatment with less side effects,
as illustrated with the use of thrombopoietin receptor agonist in
the case of thrombocytopenia.21 The immunology-directed ratio-
nale of changes identified in our preclinical model identified
CTLA4-Ig, a soluble version of CTLA4, as a key therapeutic
candidate.
CTLA4-Ig meets all of the intervention criteria listed above.
First, as a potent suppressive molecule used by Treg cells for
immune suppression,22 CTLA4-Ig can be substitutive for Treg
cells. Second, CTLA4-Ig is highly effective at quenching TH2 re-
sponses.14 Third, CTLA4-Ig effectively competes with CD80/
CD86 for CD28 binding,15 countering the increased expression
of these molecules in lymphopenic dendritic cells. Because
bimonthly administration of CTLA4-Ig to Dclre1cleaky mice
resolved inflammation, prevented tissue damage, and improved
overall survival, the immunologic rationale of CTLA4-Ig selec-
tion for murine LS treatment can be regarded as validated.
Although abatacept demonstrates high efficiency in rodent
studies, when considering clinical translation, additional options
become available, with belatacept demonstrating higher affinity
toward human CD86.23
Overall, our study identified a novel mutation of ARTEMIS,
resulting in a murine preclinical model of LS. Consistent with
CD41 T cells being the driver of inflammatory disease in patients
with LS24 and based on assessment of the immunologic distur-
bances observed, CTLA4-Ig proved an effective drug to prevent
disease manifestation and increase survival. By contrast, no
improvement was observed in the increased incidence of lym-
phoma in these mice, which mirrors the patient’s presentation,4
indicating a mechanistically independent origin for the oncolog-
ical components of disease. In addition, colitis seems to be resis-
tant to CTLA4-Ig treatment. This observation is in accordance
with clinical trials that showed failure of CTLA4-Ig in the treat-
ment of patients with Crohn disease or ulcerative colitis25 second-
ary to the resistance of inhibition of TH17 by CTLA4.
21 Together,
these results call for a carefully controlled trial of CTLA4-Ig
treatment of patients with OS/LS to investigate the potential for
treating the autoimmune/inflammatory components of disease.
Key messages
d The Dclre1cleaky mouse recapitulates the symptoms and
immunologic features of patients with LS/OS.
d CTLA4-Ig efficiently controls inflammation in these mice
through tight regulation of CD41 T cells.
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FIG E1. T-cell developmental defects in Dclre1cleaky mice. Thymi from 8- to 10-month-old wild-type and
Dclre1cleaky mice (Fig E1, A-C) or 10-week-old mice (Fig E1, D-F) were analyzed for cell numbers and T-
cell subsets by using flow cytometry. A, Representative flow cytometric plot from the thymus, including
2 mice within the Dclre1cleaky phenotype spectrum. B and C, Thymocyte subset absolute cell numbers for
double-negative (DN) and double-positive (DP; Fig E1, B) and the CD41 and CD81 single-positive (SP)
and Treg cell (Fig E1, C) subsets. D, Representative flow cytometric plot for mature (CD31CD692) and imma-
ture (CD31CD691) cells within CD41 and CD81 SP subsets. E, Representative flow cytometric plot for the
presence of recirculating cells (CD242Qa21) within CD31CD692 or CD31CD691 cells in CD41 and CD81
SP subsets. F, Percentage of recirculating T cells in the mature CD31CD692 subsets of the CD41 and
CD81 SP compartment. Median and individual data points are shown. Fig E1, B and C, Pooled data from
up to 11 experiments were used: wild-type mice (n 5 14) and Dclre1cleaky mice (n 5 from 24 to 26). Fig
E1, D-F, represents a single experiment: wild-type mice (n 5 4) and Dclre1cleaky mice (n 5 4).
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FIG E2. Dclre1cleaky mice have an LS phenotype in the periphery. Lymph nodes from wild-type (WT) and
Dclre1cleaky mice were evaluated at 8 weeks of age and between 8 and 10 months of age. T-cell subsets
were analyzed by using flow cytometry (A-E). A, Representative flow cytometric plot from the lymph nodes,
including 2 mice within the Dclre1cleaky phenotype spectrum. B and C, Percentage of total CD81 (Fig E2, B)
and CD41 (Fig E2, C) T cells. D, Absolute numbers of CD81 and CD41 T cells in the spleen at 8 weeks of age.
E, Percentage of Treg cells (CD41Foxp31 cells) in the lymph nodes. F,NKG2D geometric mean fluorescence
expression (gMFI) in splenic natural killer cells in 10-week-old mice. G, CD69 and Ly49D percentages in
splenic natural killer cells in 10-week-old mice. Median and individual data points are shown. Fig E2, B-E,
Pooled data from up to 11 experiments are shown: wild-type 8-week-old mice (n 5 3), Dclre1cleaky 8-
week-old mice (n 5 8), wild-type 8- to 10-month-old mice (n 5 14), and Dclre1cleaky 8- to 10-month-old
mice (n 5 from 26 to 27). Fig E2, F and G, represent a single experiment: wild-type mice (n 5 4) and Dclre1-
cleaky mice (n 5 4).
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FIG E3. Dclre1cleaky have increased T-cell activation and proinflammatory cytokines in serum. Lymph nodes
fromwild-type (WT) andDclre1cleakymicewere evaluated at 8 weeks of age and between 8 and 10months of
age (Fig E3, A-C, E, and F). T-cell subsets were analyzed by using flow cytometry.A, Percentage of CD41 and
CD81 T cells expressing Ki67. B and C, CD41 and CD81 T-cell subpopulations were characterized as
CD62L1CD442 naive cells, CD62L1CD441 TCM cells, and CD62L2CD441 effector memory T cells (TEM) by
using flow cytometry. Fig E3, B, shows the percentage of CD41 naive, TCM, and TEM cells. Fig E3, C, Per-
centage of CD81 naive, TCM, and TEM cells.D, Percentage of CD1221 cells within the CD81 TCM cell subsets
in 10-week-old mice. E, Percentage of CD41 and CD81 T cells expressing CD69. F, Cells from lymph nodes
were stimulated in vitro for 4 hours with phorbol 12-myristate 13-acetate/ionomycin and CD41 T cells eval-
uated for cytokine secretion, including IFN-g, IL-4, and IL-17. Median and individual data points are shown.
Fig E3, A-C, E, and F, show pooled data from up to 11 experiments: wild-type 8-week-old mice (n 5 3),
Dclre1cleaky 8-week-old mice (n 5 8), wild-type 8- to 10-month-old mice (n 5 14), and Dclre1cleaky 8- to 10-
month-old mice (n 5 from 26 to 27). Fig E3, D, represents a single experiment: wild-type mice (n 5 4)
and Dclre1cleaky mice (n 5 4).
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FIG E4. Increased short-lived effector cell counts in young Dclre1cleakymice. CD81 T cells were analyzed in a
cohort of 10-week-old mice by using flow cytometry in the spleen and lymph nodes and compared with
values in older mice (8-10 months old). A and B, Percentage of CD1271KLRG12memory precursor effector
cells (MPEC) and CD1272KLRG11 short-lived effector cells (SLEC) within CD441CD81 subsets in the spleen
(Fig E4, A) and lymph nodes (Fig E4, B). C and D, Percentage of Eomes1 and T-bet1 cells within
CD81CD441CD62L2 subsets and effector memory T cells (TEM) in the spleen (Fig E4, C) and lymph nodes
(Fig E4, D) of 10-week-old mice. E and F, Percentage of LAG31 and TIM31 cells within CD81CD441CD62L2
subsets and effector memory T cells (TEM) in the spleen (Fig E4, E) and lymph nodes (Fig E4, F) of 10-week-
oldmice. Median and individual data points are shown. Fig E4,A-F, represent a single experiment: wild-type
mice (n 5 4) and Dclre1cleaky mice (n 5 4).
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FIG E5. Dclre1cleaky mice are affected by inflammatory diseases and are at higher risk for lymphoma. Mice
from 8 to 10 months of age were evaluated at the time of death for disease incidence. A, Representative pic-
ture of a wild-type mouse. B and C, Representative picture of a Dclre1cleaky mouse, including hunched
posture and dermatitis of the ear (arrow; Fig E5, B) and tail (arrow; Fig E5, C). D, Representative picture
of a Dclre1cleaky mouse with a thymic tumor (arrow).
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FIG E6. IL-5 levels are increased in sera of Dclre1cleakymice. Sera frommice
from 8 to 10 months of age were evaluated for the presence of IL-5 by using
the MSD assay. Median and individual data points are shown. Pooled data
are from 2 experiments: wild-type (n 5 4) and Dclre1cleaky (n 5 6) mice.
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FIG E7. CTLA4-Ig treatment prevents immune pathology in Dclre1cleaky mice. Dclre1cleaky mice and litter-
mate controls (Ctrl) were followed up for a longitudinal study with or without CTLA4-Ig treatment
(25 mg/kg) every 2 weeks starting at 8 weeks of age. Mice were evaluated at 40 weeks of age. Representative
pictures are of an untreated control mouse (A), a control mouse after CTLA4-Ig treatment (B), an untreated
Dclre1cleaky mouse (C), and a Dclre1cleaky mouse after CTLA4-Ig treatment (D).
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FIG E8. CTLA4-Ig treatment decreased total CD41 T-cell counts in Dclre1cleaky mice and the overall inflam-
matory cytokine environment. Dclre1cleaky mice and littermate controls (Ctrl) received CTLA4-Ig (25 mg/kg)
every 2 weeks starting at 8 weeks of age. Mice were evaluated at 40 weeks of age for the immune cell
compartment in lymph nodes. A, Percentages of total CD41 T cells. B, Percentage of Treg cells from total
CD41 T cells. C and D, Ki671 cells (Fig E8, C) and CD691 cells (Fig E8, D) from total CD41 T cells. Median
and individual data points are shown. Representative data are of 2 experiments: untreated control mice
(n 5 from 5 to 10), untreated Dclre1cleaky mice (n 5 9), CTLA4-Ig2treated control mice (n 5 11), and
CTLA4-Ig2treated Dclre1cleaky mice (n 5 from 7 to 11).
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